Mechanism of Action and Duration of Use for Sublingual Micronized Progesterone
Mechanism of Action
Sublingual micronized progesterone acts through both genomic and non-genomic pathways, binding to progesterone receptors in target tissues to induce endometrial transformation and provide luteal support. 1
The mechanism involves:
Absorption and bioavailability: When administered sublingually, micronized progesterone achieves maximum serum concentrations within 1.5-2.3 hours, with enhanced bioavailability compared to non-micronized formulations due to the micronization process that increases surface area 1, 2
Protein binding and distribution: Progesterone is approximately 96-99% bound to serum proteins, primarily albumin (50-54%) and transcortin (43-48%), allowing for systemic distribution 1
Receptor-mediated effects: The hormone binds to nuclear progesterone receptors in the endometrium, inducing secretory transformation and providing endometrial protection when combined with estrogen therapy 3
Metabolism: Progesterone undergoes hepatic metabolism to pregnanediols and pregnanolones, which are then conjugated to glucuronide and sulfate metabolites for excretion 1
Neurosteroid effects: When administered orally or sublingually, progesterone and its metabolites act as neurosteroids, providing beneficial effects on anxiety, depression, sleep quality, and working memory 4
Recommended Duration of Use
For hormone replacement therapy in women with premature ovarian insufficiency (POI), micronized progesterone should be continued until the average age of spontaneous menopause (45-55 years). 3
Specific Duration Guidelines by Clinical Context:
Sequential regimens for endometrial protection:
- Oral micronized progesterone at 100-200 mg daily for 12-14 days per month provides endometrial protection for up to 5 years when combined with estrogen 3, 5
- Vaginal micronized progesterone at 100 mg every other day or 4% gel (45 mg/day) for at least 10 days per month provides protection for 3-5 years 5
Post-pubertal patients with iatrogenic POI:
- Treatment should continue until age 45-55 years, after which the decision to continue must be individualized based on risks, family history, and menopausal symptoms 3
Pubertal induction:
- Progestin (including micronized progesterone at 100-200 mg daily for 12-14 days per month) should be added 2-3 years after starting estrogen therapy or when breakthrough bleeding occurs 3
Dosing Specifications:
For sequential hormone replacement therapy:
- 200 mg oral or vaginal micronized progesterone daily for 12-14 days every 28 days when combined with continuous estrogen 3
- This dosing provides optimal endometrial protection while minimizing cardiovascular and thrombotic risks compared to synthetic progestins 3
Advantages over synthetic progestins:
- Micronized progesterone demonstrates superior safety profiles regarding cardiovascular risk, blood pressure effects, and venous thromboembolism risk compared to medroxyprogesterone acetate and other synthetic progestins 3
- The ESHRE guidelines specifically recommend micronized progesterone as first-line progestin therapy for women with ovarian insufficiency due to this favorable safety profile 3
Important Clinical Considerations:
Sublingual administration characteristics:
- Peak serum levels occur at 1.5 hours with sublingual administration 1
- Bioavailability is enhanced with food intake 1
- Sublingual progesterone achieves adequate serum levels (30.5 ± 15.7 ng/mL at embryo transfer) for luteal support, though slightly lower than intramuscular administration 6
Common pitfall: Transdermal micronized progesterone does NOT provide adequate endometrial protection and should not be used for this purpose 5